Social factors and age play a significant role in cervical cancer and advanced-stage disease among Danish women.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Social Factors* ; Uterine Cervical Neoplasms*/diagnosis; Female ; Humans ; Aged ; Mass Screening ; Early Detection of Cancer ; Denmark/epidemiology

Background: For cervical cancer (CC), the implementation of preventive strategies has the potential to make cervical cancer occurrence and death largely avoidable. To better understand the factors possibly responsible for cervical cancer, we aimed to examine possible differences in age and social parameters as well as screening status between women with low- or high-stage cervical cancer and matched controls.
Methods: Through the Danish Cancer Registry (DCR), women diagnosed with cervical cancer in Denmark between 1987 and 2016 were included. These were age- and residence-matched in a 1:5 ratio with controls from the general female population. The study population was sub grouped into a low-stage subpopulation with women with early-stage cervical cancer and matched controls and a high-stage subpopulation with women with late-stage cervical cancer and matched controls. Age and social parameters were compared within the subpopulations as well as between low- and high-stage cases. For part of the study population, screening attendance was examined to compare differences in adherence.
Results: Overall, we found that the risk of cervical cancer is significantly increased in socially disadvantaged women and not least non-attenders in screening. Interestingly, the high-stage subpopulation was significantly older than the low-stage subpopulation (p < 0.001), and when examining the impact of age further, we found that for cervical cancer cases, the risk of having low-stage disease decreases significantly with increasing age, whereas the risk of having high-stage disease increases significantly with increasing age. In the screening cohort, significantly less cases than controls were attenders in screening with the most pronounced differences seen in the old subpopulation (women aged 50-64 years) and in the high-stage subpopulation (p-values all < 0.001). Interestingly, when examining the risk of CC for attenders and non-attenders, we demonstrated that many social parameters continue to influence the risk of cervical cancer, even in women attending screening.
Conclusions: Older women, socially disadvantaged women, and non-attenders in screening are particularly vulnerable in terms of developing cervical cancer, especially high-stage disease. Therefore, improvements in the participating rate in screening as well as a revision of the current screening guidelines are needed.
(© 2024. The Author(s).)

PLoS One. 2015 Jul 28;10(7):e0134185. (PMID: 26218492)
Prev Med Rep. 2015 Jul 31;2:711-6. (PMID: 26844141)
Clin Infect Dis. 2016 Aug 15;63(4):519-27. (PMID: 27230391)
Eur J Cancer Prev. 2005 Oct;14(5):459-66. (PMID: 16175050)
Cancer. 2014 Jul 1;120(13):2032-8. (PMID: 24821088)
Clin Epidemiol. 2015 Nov 17;7:449-90. (PMID: 26604824)
Scand J Public Health. 2011 Jul;39(7 Suppl):103-5. (PMID: 21775365)
J Pathol. 1999 Sep;189(1):12-9. (PMID: 10451482)
Prev Med. 2017 Jan;94:31-39. (PMID: 27894911)
BMJ. 2009 Jun 16;338:b2025. (PMID: 19531549)
Gynecol Oncol. 2011 Jan;120(1):68-72. (PMID: 21035171)
Am J Obstet Gynecol. 2017 Feb;216(2):151.e1-151.e9. (PMID: 27746152)
J Natl Cancer Inst. 2008 May 7;100(9):622-9. (PMID: 18445828)
Prev Med. 2007 Aug-Sep;45(2-3):93-106. (PMID: 17651792)
J Womens Health (Larchmt). 2010 Sep;19(9):1675-81. (PMID: 20799924)
Cancer Epidemiol. 2015 Aug;39(4):650-5. (PMID: 26055147)
PLoS One. 2014 Aug 18;9(8):e104901. (PMID: 25133662)
Papillomavirus Res. 2016 Dec;2:78-84. (PMID: 29074189)
Cancer Causes Control. 2005 May;16(4):463-74. (PMID: 15953989)
Eur J Cancer. 2015 Nov;51(16):2375-85. (PMID: 26296294)
Prev Med. 2019 Jun;123:55-64. (PMID: 30796926)
Asian Pac J Cancer Prev. 2013;14(11):6445-50. (PMID: 24377548)
Cancer Causes Control. 2015 Aug;26(8):1105-16. (PMID: 26033777)
Clin Epidemiol. 2019 Nov 08;11:969-980. (PMID: 31814770)
Eur J Cancer. 2000 Nov;36(17):2198-204. (PMID: 11072204)
Int J Cancer. 2008 Apr 15;122(8):1854-8. (PMID: 18067129)
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S43-103. (PMID: 17161167)
Prev Med. 2018 Sep;114:188-192. (PMID: 29981791)
Scand J Public Health. 2011 Jul;39(7 Suppl):42-5. (PMID: 21775350)
BMC Womens Health. 2019 Feb 26;19(1):38. (PMID: 30808349)
Cancer Epidemiol. 2016 Jun;42:108-14. (PMID: 27100836)
Eur J Gynaecol Oncol. 2010;31(2):174-80. (PMID: 20527234)
J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716)
N Engl J Med. 2020 Oct 1;383(14):1340-1348. (PMID: 32997908)
Acta Oncol. 2015;54(8):1136-43. (PMID: 25800858)
Acta Obstet Gynecol Scand. 2017 Feb;96(2):150-157. (PMID: 27861705)
Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):835-42. (PMID: 22434535)
BJOG. 2012 Jan;119(1):26-32. (PMID: 21668764)
Cancer. 2017 May 15;123(6):1044-1050. (PMID: 28112816)
Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):242s-247s. (PMID: 12646519)
Cancer. 1994 Jan 1;73(1):140-7. (PMID: 8275416)
BMJ Open. 2018 Oct 2;8(10):e024477. (PMID: 30282687)
Gynecol Oncol. 2016 Sep;142(3):395-400. (PMID: 27388696)
CMAJ. 2016 Sep 6;188(12):E281-E288. (PMID: 27378467)
Eur J Public Health. 2013 Oct;23(5):879-83. (PMID: 22711786)
Front Oncol. 2015 Jun 24;5:141. (PMID: 26157706)
Gynecol Obstet Fertil. 2007 Sep;35(9):764-71. (PMID: 17765001)
Prev Med. 2017 Aug;101:60-66. (PMID: 28502577)
Coll Antropol. 2007 Apr;31 Suppl 2:17-22. (PMID: 17600933)
BMJ. 2012 Mar 01;344:e804. (PMID: 22381675)
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):95-103. (PMID: 27624639)
Br J Cancer. 2016 Mar 1;114(5):576-81. (PMID: 26794278)
Vaccine. 2014 Apr 1;32(16):1828-33. (PMID: 24530938)
Ann Epidemiol. 2014 Nov;24(11):849-54. (PMID: 25241148)
Clin Epidemiol. 2016 Oct 25;8:655-660. (PMID: 27826216)
Int J Cancer. 2012 Feb 15;130(4):937-47. (PMID: 21437898)
Eur J Cancer. 1993;29A(5):745-9. (PMID: 8471334)
Int J Cancer. 2015 Mar 15;136(6):E677-84. (PMID: 25178683)
Scand J Public Health. 2011 Jul;39(7 Suppl):91-4. (PMID: 21775362)
Prev Med Rep. 2020 Apr 28;19:101106. (PMID: 32426214)
Scand J Public Health. 2011 Jul;39(7 Suppl):22-5. (PMID: 21775345)
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S43-S103. (PMID: 29644676)
Prev Med. 2018 Jun;111:94-100. (PMID: 29501474)
BMJ Open. 2015 Jul 24;5(7):e007735. (PMID: 26209119)
J Med Screen. 2006;13(1):41-6. (PMID: 16569305)
Br J Cancer. 2004 May 4;90(9):1756-9. (PMID: 15208619)
Vaccine. 2013 Dec 17;32(1):33-8. (PMID: 24211170)
Scand J Public Health. 2011 Jul;39(7 Suppl):30-3. (PMID: 21775347)
Eur J Cancer. 2017 Jul;80:30-38. (PMID: 28535495)
Am J Prev Med. 2017 Sep;53(3):392-395. (PMID: 28473240)
Lancet. 2019 Aug 10;394(10197):497-509. (PMID: 31255301)
Cancer Epidemiol. 2014 Apr;38(2):174-80. (PMID: 24447699)
Curr Probl Cancer. 2007 May-Jun;31(3):157-81. (PMID: 17543946)
Clin Epidemiol. 2018 Aug 23;10:1027-1036. (PMID: 30197540)
Br J Cancer. 2008 Apr 8;98(7):1292-4. (PMID: 18334971)

30-206-343 IMK Almene Fond

Keywords: Cervical cancer screening; Denmark; Epidemiology; Nationwide; Non-attendance; Screening guidelines; Social parameters

Date Created: 20240223 Date Completed: 20240226 Latest Revision: 20240227

20240227

PMC10893677

10.1186/s12885-024-11994-4

38395802